نتائج البحث - Tim Holland‐Letz

تنقيح النتائج
  1. 1
    Accounting for differential exclusions in the NordICC trial discloses stronger-than-reported effects of screening colonoscopy

    Accounting for differential exclusions in the NordICC trial discloses stronger-than-reported effects of screening colonoscopy حسب Hermann Brenner, Tim Holland‐Letz, Michael Hoffmeister, Thomas Heisser

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Nucleated red blood cells in the blood of medical intensive care patients indicate increased mortality risk: a prospective cohort study

    Nucleated red blood cells in the blood of medical intensive care patients indicate increased mortality risk: a prospective cohort study حسب Axel Stachon, Elmar Segbers, Tim Holland‐Letz, Reiner Kempf, Steffen Hering, Michael Krieg

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    The Clinical Impact of Additional Late PET/CT Imaging with <sup>68</sup>Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer

    The Clinical Impact of Additional Late PET/CT Imaging with <sup>68</sup>Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer حسب Ali Afshar‐Oromieh, Lars Peter Sattler, Walter Mier, Boris Hadaschik, Jürgen Debus, Tim Holland‐Letz, Klaus Kopka, Uwe Haberkorn

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: A 12-year single-center survey

    Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: A 12-year single-center survey حسب Anke Furck, Anselm Uebing, Jan Hinnerk Hansen, Jens Scheewe, Olaf Jung, Günther Fischer, Carsten Rickers, Tim Holland‐Letz, Hans‐Heiner Kramer

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    miR-339-3p Is a Tumor Suppressor in Melanoma

    miR-339-3p Is a Tumor Suppressor in Melanoma حسب Claudia E.M. Weber, Chonglin Luo, Agnes Hotz‐Wagenblatt, Adriane Gardyan, Theresa Kordaß, Tim Holland‐Letz, Wolfram Osen, Stefan B. Eichmüller

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy

    Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy حسب Verena Haselmann, Christoffer Gebhardt, Ingrid Brechtel, Angelika Duda, Claudia Czerwinski, Antje Sucker, Tim Holland‐Letz, Jochen Utikal, Dirk Schadendorf, Michael Neumaier

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients

    Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients حسب Ali Afshar‐Oromieh, Marcelo Livorsi da Cunha, Jairo Wagner, Uwe Haberkorn, Nils Debus, Wolfgang Weber, Matthias Eiber, Tim Holland‐Letz, Isabel Rauscher

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Reproducibility and reliability of the ankle—brachial index as assessed by vascular experts, family physicians and nurses

    Reproducibility and reliability of the ankle—brachial index as assessed by vascular experts, family physicians and nurses حسب Tim Holland‐Letz, Heinz G. Endres, Stefanie Biedermann, Matthias Mahn, Joachim Kunert, Sabine Groh, David Pittrow, Peter von Bilderling, R Sternitzky, Curt Diehm

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

    Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 حسب Ali Afshar‐Oromieh, Uwe Haberkorn, Christian M. Zechmann, Thomas Armor, Walter Mier, Fabian Spohn, Nils Debus, Tim Holland‐Letz, John W. Babich, Clemens Kratochwil

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Response Prediction of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

    Response Prediction of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase حسب Hendrik Rathke, Tim Holland‐Letz, Walter Mier, Paul Flechsig, Eleni Mavriopoulou, Manuel Röhrich, Klaus Kopka, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn, Clemens Kratochwil

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer

    Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer حسب Frederik L. Giesel, Florian Sterzing, HP Schlemmer, Tim Holland‐Letz, Walter Mier, Maria Rius, Ali Afshar‐Oromieh, Klaus Kopka, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Correlation Between SUV<sub>max</sub> and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging

    Correlation Between SUV<sub>max</sub> and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging حسب Frederik L. Giesel, Florian Schneider, Clemens Kratochwil, Daniel Rath, Jan Hendrik Moltz, Tim Holland‐Letz, Hans‐Ulrich Kauczor, Lawrence H. Schwartz, Uwe Haberkorn, Paul Flechsig

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score

    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score حسب Anna S. Berghoff, Fabian Wolpert, Tim Holland‐Letz, Romina Koller, Georg Widhalm, Brigitte Gatterbauer, Karin Dieckmann, Peter Birner, Rupert Bartsch, Christoph Zielinski, Michael Weller, Matthias Preusser

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

    Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer حسب Ali Afshar‐Oromieh, Christian M. Zechmann, A. Malcher, Matthias Eder, Michael Eisenhut, Heinz Linhart, Tim Holland‐Letz, Boris Hadaschik, Frederik L. Giesel, Jürgen Debus, Uwe Haberkorn

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

    Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab حسب Christoffer Gebhardt, Alexandra Sevko, Huanhuan Jiang, Ramtin Lichtenberger, Maike Reith, Kathrin Tarnanidis, Tim Holland‐Letz, Ludmila Umansky, Philipp Beckhove, Antje Sucker, Dirk Schadendorf, Jochen Utikal, Viktor Umansky

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer

    Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer حسب Ali Afshar‐Oromieh, Nils Debus, Monika Uhrig, Thomas A. Hope, Michael J. Evans, Tim Holland‐Letz, Frederik L. Giesel, Klaus Kopka, Boris Hadaschik, Clemens Kratochwil, Uwe Haberkorn

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective

    Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective حسب Tanja Jutzi, Eva Krieghoff‐Henning, Tim Holland‐Letz, Jochen Utikal, Axel Hauschild, Dirk Schadendorf, Wiebke Sondermann, Stefan Fröhling, Achim Hekler, Max Schmitt, Roman C. Maron, Titus J. Brinker

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions

    The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions حسب Ali Afshar‐Oromieh, Henrik Hetzheim, Clemens Kratochwil, Martina Benešová, Matthias Eder, Oliver Neels, Michael Eisenhut, W Kübler, Tim Holland‐Letz, Frederik L. Giesel, Walter Mier, Klaus Kopka, Uwe Haberkorn

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    The accuracy of free-hand cup positioning - a CT based measurement of cup placement in 105 total hip arthroplasties

    The accuracy of free-hand cup positioning - a CT based measurement of cup placement in 105 total hip arthroplasties حسب Guido Saxler, A. Marx, D Vandevelde, Ulrich Langlotz, Moritz Tannast, M. Wiese, Uwe Michaelis, G. W. H. Kemper, Paul Alfred Grützner, R. Steffen, Marius von Knoch, Tim Holland‐Letz, K. Bernsmann

    منشور في 2004
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

    The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer حسب Ali Afshar‐Oromieh, Eleni Avtzi, Frederik L. Giesel, Tim Holland‐Letz, Heinz Linhart, Matthias Eder, Michael Eisenhut, Silvan Boxler, Boris Hadaschik, Clemens Kratochwil, Wilko Weichert, Klaus Kopka, Jürgen Debus, Uwe Haberkorn

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: